

Ø1001/003

# FOLEY, HOAG & ELIOT LLP

ONE POST OFFICE SQUARE BOSTON, MASSACHUSETTS 02109-2170

TELEPHONE 617-832-1000

FACSIMILE 617-832-7000

## FACSIMILE COVER SHEET

January 19, 2001

TO:

Examiner B. Loeb

Group Art Unit: 1636

FAX #: (703) 305 7939

CONFIRMATION #: (703) 605 1197

CLIENT-MATTER #: USSN 09/466.568 (Our Ref. APV-316.16)

FROM: Isabelle M. Clauss

EXT: 1177 USER#:

6171

TOTAL PAGES SENT: including cover sheet 3

MESSAGE -

Please deliver to Examiner B. Loeb

#### IMPORTANT -- PLEASE READ

The information contained in this fresimile message is intended only for the personal and confidential use of the designated recipients named above. This message may be an attorney-client communication and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by relephone and return the original message to us by mail. Thank you,

IF THERE ARE ANY PROBLEMS WITH THIS TRANSMISSION PLEASE TELEPHONE THE SENDER.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Crabtree et al.

Group Art Unit: 1636

Serial No.: 09/466,568

Examiner: Loeb, B.

Filed: Dec. 17, 1999

For: Regulated Transcription of Targeted Genes

Docket No.: APV-316.16

Assistant Commissioner for Patents Washington, D.C. 20231

and Other Biological Events

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being facsimile transmitted to: Assistant Commissioner for Patents, Washington, D.C. 20231, at fax No. (703) 305 7939 on the date set form below.

January 19, 2001 B

Date of Signature and Mail Deposit

### PRELIMINARY AMENDMENT

Dear Sir:

Prior to substantive examination of the above-referenced patent application, please amend the application as follows:

### In the claims:

Please amend the remaining claims as follows:

- 32. (Amended) A method of claim [30] 31 wherein the cells are grown in a culture medium and the exposing is effected by adding the ligand to the culture medium.
- (Amended) A method of claim [30] 31 wherein the cells are present within a host organism and the exposing is effected by administering the ligand to the host organism.
- 38. (Amended) A kit of claim [36] 37 which further comprises a ligand to which one or more of the chimeric proteins encoded by the DNA construct(s) bind.
  - (Amended) A kit of claim [37] 38 which further comprises a monometic ligand reagent as an antagonist for ligand-chimeric protein binding.
- 48. (Amended) A mammal of claim [45] 47 which is a mouse or other rodent or a human.